Shots: GSK, Evotec, J&J, Otsuka, the Bill & Melinda Gates Medical Research Institute and its foundation have launched the ‘PAN-TB collaboration’ project to collaboratively accelerate the development of novel TB […]readmore
Tags : Forms
Shots: The approval is based on P-III ASCLEPIOS I and II studies involves assessing of ofatumumab (20mg, SC) vs Aubagio (14mg oral tablets) in 1882 adults with MS between the […]readmore
Shots: The JV leverages the expertise of three companies that includes Wilson Wolf’s G-Rex technology, BioTechne’s proteins, reagents, media, and gene-editing technologies and Fresenius Kabi’s Lovo cell processing system washes, […]readmore
Shots: The approval is based on the Nix-TB trial assessing bedaquiline, pretomanid and linezolid collectively called BPaL regimen in 109 patients with XDR-TB treatment-intolerant or non-responsive MDR-TB across three sites […]readmore
Shots: The acceptance of NDA is based on P-III SUNBEAM and RADIANCE Part B study results assessing oral ozanimod (0.92/0.46 mg) in 1,346 & 1,320 patients with RMS across 152 […]readmore
Shots: The approval is based on the results of P-III PARADIGMS study assessing Gilenya (0.5mg/ 0.25mg, qd) vs Extavia (interferon beta-1a, qw) in 215 patients with MS aged 10 to […]readmore